ArticleCancer immunology, immunotherapy : CII2025
Efficacy of PRaG therapy in microsatellite-stable metastatic colorectal cancer: a comparative analysis of PD-1/PD-L1 inhibitor-based combination therapies.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article.Clinical drug investigation · 2026Review
- Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials.Cancer immunology, immunotherapy : CII · 2026Article
- PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost (95%) metastatic colorectal cancers (mCRCs) exhibit microsatellite stability (MSS) and proficiency in DNA mismatch repair (pMMR), leading to resistance to immunotherapy. To overcome this, the combination of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors with other therapeutic strategies has been explored. This study evaluated the efficacy of PRaG therapy-a combination of PD-1 inhibitors, radiotherapy, and granulocyte‒macrophage colony-stimulating factor-in comparison with other combination therapies.
methodsMSS/pMMR mCRC patients receiving PD-1/PD-L1 inhibitor combination therapy at the Second Affiliated Hospital of Soochow University were analyzed. Patients were grouped by therapy type, and SPSS 26.0 was used to assess clinical features, survival outcomes, tumor response, and adverse reactions.
resultsA total of 101 patients were enrolled and categorized into three groups: a PD-1/PD-L1 inhibitor combined with chemotherapy group (n = 35), a tyrosine kinase inhibitor group (n = 36), and a PRaG therapy group (n = 30). Clinical outcomes, including median progression-free survival (mPFS), median overall survival (mOS), response rates, and prognostic factors, were analyzed using SPSS 26.0. The prognostic analyses being conducted only in the PRaG therapy group. PRaG therapy group had the highest objective response rate (20.0%) and the longest mPFS (4.5 months, P < 0.05). However, no significant difference in mOS was observed among the groups. Prognostic analysis identified baseline peripheral lymphocyte counts, CD8 + T cell counts, and IL-17A levels as independent factors influencing treatment outcomes.
conclusionsPD-1/PD-L1 inhibitor-based therapies show clinical efficacy in MSS/pMMR mCRC patients. PRaG therapy has potential advantages over chemotherapy or tyrosine kinase inhibitors, with CD8 + T cell counts and IL-17A levels being key prognostic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.